Keyword: Shire

Flemming Ornskov, Shire’s most recent CEO and who orchestrated the Baxalta takeover and later the selloff to Takeda, is now Galderma's CEO.

Original Takeda employees alleged faced unfair changes in their roles and got different incentive plans during the integration.

SVB Leerink analysts are explaining why they like AbbVie's planned $63 billion acquisition of Allergan, and it all boils down to diversification.

Ex-Shire CFO Jeff Poulton has landed at Alnylam. He'll replace current CFO Manmeet Soni, "arguably the best CFO in mid-cap biotech," one analyst said.

The majority of investors backed a proposal that would allow Takeda to claw back executive pay should the Shire deal not live up to expectations.

After closing its $64 billion buyout of Shire, Takeda planned to move its headquarters—and up to 1,000 workers—to the Boston area.

Takeda says supplies of primary immune deficiency treatment Gammagard Liquid will remain spotty this year as it ramps up production at a new plant.

Takeda, in its first year counting the Shire business, managed to turn up revenue growth. But the upcoming fiscal year could be a different story.

AbbVie and Shire investors struck an agreement to settle claims AbbVie misled the public about its reasons for pursuing Shire.

Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.